Ironvine Capital Partners LLC Has $15.35 Million Stock Holdings in Labcorp Holdings Inc. $LH

Ironvine Capital Partners LLC trimmed its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 16.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,819 shares of the medical research company’s stock after selling 10,730 shares during the quarter. Labcorp accounts for about 1.3% of Ironvine Capital Partners LLC’s portfolio, making the stock its 24th largest position. Ironvine Capital Partners LLC owned 0.07% of Labcorp worth $15,349,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Nwam LLC increased its stake in shares of Labcorp by 10.6% in the second quarter. Nwam LLC now owns 1,078 shares of the medical research company’s stock valued at $302,000 after buying an additional 103 shares during the period. Rehmann Capital Advisory Group raised its holdings in Labcorp by 3.1% during the 2nd quarter. Rehmann Capital Advisory Group now owns 3,655 shares of the medical research company’s stock worth $1,023,000 after purchasing an additional 110 shares during the last quarter. Camelot Portfolios LLC lifted its holdings in Labcorp by 44.3% in the second quarter. Camelot Portfolios LLC now owns 1,835 shares of the medical research company’s stock valued at $514,000 after buying an additional 563 shares during the period. Greenleaf Trust grew its stake in Labcorp by 10.3% during the second quarter. Greenleaf Trust now owns 4,592 shares of the medical research company’s stock worth $1,286,000 after purchasing an additional 428 shares during the period. Finally, New Mexico Educational Retirement Board lifted its position in shares of Labcorp by 7.8% during the 2nd quarter. New Mexico Educational Retirement Board now owns 4,129 shares of the medical research company’s stock valued at $1,156,000 after acquiring an additional 300 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Trading Down 1.6%

Shares of LH stock opened at $327.36 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. The company has a market capitalization of $26.55 billion, a price-to-earnings ratio of 27.08, a PEG ratio of 1.92 and a beta of 0.88. Labcorp Holdings Inc. has a 52-week low of $244.52 and a 52-week high of $341.80. The company has a 50-day simple moving average of $303.16 and a two-hundred day simple moving average of $279.57.

Labcorp (NYSE:LH) last announced its earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Research analysts anticipate that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio is 23.82%.

Insider Activity

In related news, EVP Bryan T. Vaughn sold 234 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the transaction, the executive vice president owned 6,746 shares in the company, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kerrii B. Anderson sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the sale, the director owned 6,563 shares of the company’s stock, valued at $2,087,165.26. This trade represents a 31.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 9,681 shares of company stock worth $3,027,677. 0.84% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Barclays lifted their price objective on shares of Labcorp from $290.00 to $320.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Bank of America upped their target price on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Piper Sandler raised their price target on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $306.00 price objective on shares of Labcorp in a research note on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Labcorp presently has a consensus rating of “Moderate Buy” and an average target price of $330.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.